Compare Edwards Lifesciences Corporation Common Stock (EW) vs Unum Group Common Stock (UNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Edwards Lifesciences Corporation Common Stock vs Unum Group Common Stock — how do they compare? Edwards Lifesciences Corporation Common Stock trades at $87.08 (market cap $49.15B), while Unum Group Common Stock trades at $91.42 (market cap $14.57B). The key difference: Edwards Lifesciences Corporation Common Stock is far larger — about 3.4× Unum Group Common Stock's market cap, and Unum Group Common Stock pays a 2.19% dividend while Edwards Lifesciences Corporation Common Stock pays none. Which is the better fit depends on your goals.
| EW | UNM | |
|---|---|---|
Market Cap | $49.15B | $14.57B |
Volume | 3,642,969 | 1,461,588 |
Sector | Health | Financials |
52-Week High | $95.18 | $96.57 |
52-Week Low | $72.65 | $70.66 |
Enterprise Value | $45.60B | $18.14B |
Typical Hold Time | — | 0 Days |
Dividend Yield | — | 2.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Edwards Lifesciences (EW) trades at $85.27, down 1.3% with bearish technical signals. The company maintains strong fundamentals with 77.84% gross margins and recent FDA approval for the AUTUS pediatric valve. Despite a high P/E of 50.76, analysts project 20% upside to the $102.44 consensus target. Recent earnings show mixed results with Q1 and Q2 beats but a Q4 miss.
EW faces valuation concerns with declining net income margins from 17.69% to 15.43% year-over-year. Technical resistance at $86-89 and negative cash flow trends present near-term challenges. However, institutional accumulation and zero sell ratings suggest long-term confidence in structural heart growth platforms.
Unum Group (UNM) trades at $92.05, down 0.5% with neutral technical signals. The stock shows mixed earnings performance with Q1 2026 beating estimates but Q4 2025 and Q2 2026 missing expectations. Analyst consensus is positive with 50% buy ratings and a $101 price target representing 9.7% upside. The company maintains stable profitability with 5.31% net margin and recently announced a $1 billion share repurchase program to enhance shareholder returns.
UNM presents a balanced investment case with strong institutional support and shareholder-friendly capital returns, though earnings consistency remains a concern. The stock trades at reasonable valuations (P/E 21.36, P/S 1.15) with potential upside to analyst targets. Key risks include premium growth sustainability and claims experience volatility in the insurance operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Edwards Lifesciences Corporation Common Stock
Edwards Lifesciences develops medical technologies for structural heart disease. Its products include transcatheter aortic-valve replacement, mitral and tricuspid therapies, and surgical structural-heart technologies.
Read more on EW →About Unum Group Common Stock
Unum Group provides workplace benefits, including disability, life, accident, critical illness, dental, and vision insurance, along with leave management services. It serves employers through its Unum US, Unum International, and Colonial Life segments, distributing coverage via brokers and independent agents.
Read more on UNM →
